Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
about
Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic AnalysisUltra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeMechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavirClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentAntiviral therapy and resistance with hepatitis B virus infection.Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutationsReview of hepatitis B therapeutics.Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.The HBV drug entecavir - effects on HIV-1 replication and resistanceSulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method.Entecavir: a potent new antiviral drug for hepatitis B.Agents in clinical development for the treatment of chronic hepatitis B.Treatment of hepatitis B in decompensated liver cirrhosis.TarPred: a web application for predicting therapeutic and side effect targets of chemical compounds.New aspects on the natural history of chronic hepatitis B infection: implication for therapy.Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerasesAntivirals and antiviral strategies.Entecavir for the treatment of chronic hepatitis B.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.The laboratory diagnosis of hepatitis B virus.Personal view: the management of chronic hepatitis B infection.Targets of emerging therapies for viral hepatitis B and C.Future prospectives for the management of chronic hepatitis B.Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cellNoncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells.Entecavir for the long-term treatment of chronic hepatitis B.Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.Update on entecavir in the management of severe forms of Hepatitis B.Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.Synthesis and anti-HIV study of novel acyclic guanine derivatives.Understanding the molecular basis of HBV drug resistance by molecular modeling.Inhibition of hepatitis B virus polymerase by entecavir.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
P2860
Q27317068-5D789CA6-7FB1-4AAC-BE3E-6990C5BA64C9Q28484005-385FA58D-2662-4935-9160-593BA0DC7C04Q28748931-91281369-B10E-4CB7-A3AB-BC2A432F5FE2Q33206221-C860EB52-FB59-4440-A430-7C0EE5C716EAQ33267067-34DAC148-B0A8-480A-8239-776CC1D443DBQ33787531-3D748EBC-6FF0-4DD8-80ED-9B62FF37305CQ33940140-9FADF7DF-AB39-4DFE-AABE-C20F0F556A2DQ34296410-4EB694F5-4F3B-433C-8858-8956EC923F17Q34538293-BB1FC848-3F8D-4224-85A5-40B631219A34Q34639926-049F1498-48DC-4340-A6D8-63911C9F1AEEQ34663350-869C83D0-EFAB-407C-ACA0-E2F986FB1FA5Q35001215-F2C7075F-4A31-459C-B6BD-A0FBF50E057CQ35094702-655F912B-E45D-4796-966A-030CC4E974DBQ35185749-980042AC-F422-4646-8116-502A8F88BB1FQ35207784-EF7E8630-6022-46AD-8A1E-03C1D9B70501Q35562182-B5497A50-3FDD-40F1-90AB-35B0E300C736Q35628953-62B9EAE5-11CF-441C-AFE0-6C0A7128AAC4Q35675387-2982CC2D-EF39-4629-9898-A34239A2FD29Q35889586-CDDAA548-A051-45C5-85CC-B8AE50EE6710Q35964745-08526790-F5D7-4540-AA69-869AEC43AC55Q35987869-513760F5-4BC1-4F23-9D85-DD60515167FEQ36108952-305B07EE-1F51-4919-ADB1-313A305200C6Q36171000-AEC3C058-3797-4FD3-A93F-8A906AEDB4DCQ36435893-F3463C85-2DE2-4848-B8F5-66A6E59EEAB0Q36653655-A1BD2528-2650-4EF9-9B85-288E093E7A76Q36841719-3BE2D21B-542B-4B6D-8480-EB9881A52A2BQ36843555-E627FECC-0FA7-46DE-859C-3CB4D45DBADBQ37009852-41AB6306-4697-4B06-B6FC-E999AD9B2A6FQ37124000-8C929C54-3100-4C82-A52C-81BB3F3E6457Q37212962-9129105B-ED7F-4108-87FD-3ED60A3B1757Q37626058-D4362018-D8D9-4D0C-B62E-2655A364F8C8Q38071396-774514C4-9DBB-4F1B-A07A-4FF1FCD60ADDQ38096069-F7F1180A-1D68-4498-8DF9-08D714A0ED46Q38201711-C8A57F2D-7CC7-4456-A8E6-5756B1122083Q39649139-4FA97BEF-531B-431B-A32C-BAD488515165Q40006328-ABBDAE09-6ABE-48CB-A787-58F1FD15DD33Q40023105-965F8828-D815-4411-9595-F22AC68163FEQ40052006-C2F2C3C9-A4BA-413B-AEB7-EF16689F01B2Q40176633-24B5C25F-D581-47C0-9D7C-4322E6CE6C4AQ40312810-92D21448-0185-46B8-9F59-0DED5882268C
P2860
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@en
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@nl
type
label
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@en
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@nl
prefLabel
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@en
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@nl
P2093
P2860
P1476
Efficacies of entecavir agains ...... ombinant polymerases in vitro.
@en
P2093
D Hernandez
G Yamanaka
R J Colonno
S Weinheimer
P2860
P304
P356
10.1128/AAC.46.8.2525-2532.2002
P407
P577
2002-08-01T00:00:00Z